AUPH
Aurinia Pharmaceuticals Inc.
Key Financials
Net Income
$287.2M
↑ 36.2%
Revenue
$283.1M
↑ 267.1%
Operating Income
$104.9M
↑ 215.6%
Total Assets
$751.6M
↑ 36.5%
Total Liabilities
$170.3M
↓ 1.7%
Shareholders' Equity
$581.3M
↑ 54.0%
Cash & Equivalents
$80.2M
↓ 3.9%
EPS (Diluted)
$2.07
↑ 35.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SC TO-T | 4/13/2026 | View on SEC |
| 8-K | 4/3/2026 | View on SEC |
| 3 | 4/2/2026 | View on SEC |
| 3 | 4/2/2026 | View on SEC |
| SCHEDULE 13D/A | 3/25/2026 | View on SEC |
| 8-K | 3/23/2026 | View on SEC |
| 4 | 3/10/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| SCHEDULE 13D/A | 3/3/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AUPH |
| Company Name | Aurinia Pharmaceuticals Inc. |
| CIK | 1600620 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 250-744-2487 |